, Tracking Stock Market Picks
Enter Symbol:
Anthera Pharmaceuticals, Inc. (ANTH) [hlAlert]

up 51.00 %

Anthera Pharmaceuticals, Inc. (ANTH) rated Buy by Jefferies

Posted on: Tuesday,  Mar 5, 2013  8:25 AM ET by Jefferies

Jefferies rated Buy Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) on 03/05/2013, when the stock price was $5.00. Since
then, Anthera Pharmaceuticals, Inc. has gained 51.00% as of 01/13/2016's recent price of $7.55.
If you would have followed this Jefferies's recommendation on ANTH, you would have gained 51% of your investment in 1044 days.

Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Jefferiess' research efforts cover U.S. & International equity, high yield, convertibles, derivatives and option strategies, investment grade fixed income, post-reorganization securities, as well as special situations and quantitative research. Our team of more than 150 research professionals covers nearly 1,200 companies in more than 40 industries worldwide. Our analysts focus on identifying emerging industry themes while providing in-depth, thought provoking, objective research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/5/2013 8:25 AM Buy
as of 12/13/2013
1 Week up  2.42 %
1 Month down  -8.92 %
3 Months down  -19.12 %
1 YTD down  -40.80 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy